Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292770 | 0.88 | RAB9A (0.83) | CYP2C19RAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL24071815 | 0.88 | RAB9A (0.83) | CYP2C19RAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL6079016 | 0.88 | ALDH1A1 (0.72) | CYP2C19RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6792419 | 0.87 | KMT2A (0.88) | ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL612760 | 0.87 | CYP2C19 (1.00) | CYP2C19RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL12215903 | 0.85 | CYP2C19 (0.79) | CYP2C19RAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15362323 | 0.84 | ALDH1A1 (1.00) | CYP2C19RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL24072673 | 0.84 | RAB9A (0.98) | CYP2C19RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7694604 | 0.84 | ALDH1A1 (0.77) | CYP2C19RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL7534615 | 0.84 | ALDH1A1 (1.00) | CYP2C19RAB9AALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
| EP-0783500-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010022-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | CYP2C19 711/4885RAB9A 1753/4885ALDH1A1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.